Eric Engeron, MD
Interventional Cardiology · Houma, LANPI 1154328144
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,095 of the $4,687 with a category attached, or 66.0%. 24 manufacturers reported payments, led by Janssen Research & Development, LLC at 24.1% of the total. Reporting peaked in 2023 at $1,888 and has fallen 77.0% since, to $435 in 2025. That places this record below the midpoint for interventional cardiology clinicians in LA, where the typical reported total is $9,970.
Across 83 payments — averaging $56.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Inari Medical, Inc.$752
- Medtronic$475
- Abiomed$270
- Boehringer Ingelheim$251
- Ancora Heart, Inc.$241
- plus $2K from 18 others
Across 72 payments — averaging $5168.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$317K
- CSL Behring$55K
What the payments were for
- Travel & lodging$1,59334%
- Food & beverage$3,09566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $1,131 |
| Inari Medical, Inc. | 3 | $752 |
| Medtronic(2 entities) | 13 | $475 |
| Abiomed | 16 | $270 |
| Boehringer Ingelheim | 3 | $251 |
| Ancora Heart, Inc. | 1 | $241 |
| E.r. Squibb & Sons, L.L.C. | 3 | $160 |
| Johnson & Johnson | 3 | $150 |
| Kestra Medical Technology Services, Inc. | 8 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $141 |
| Amgen | 2 | $139 |
| Imperative Care, Inc | 2 | $139 |
| AstraZeneca | 1 | $125 |
| Itamar Medical Inc | 1 | $112 |
| Abbott | 2 | $110 |
| Boston Scientific | 5 | $106 |
| Angiodynamics, Inc. | 1 | $99 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Stryker | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Terumo Medical Corporation | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Shockwave Medical, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FlowTriever$729
- ClotTriever$729
- COREVALVE EVOLUT R$321
- AccuCinch$241
- JARDIANCE$240
- FARXIGA$125
- Repatha$123
- WatchPat$112
- LifeVest$100
How this compares
$4,687 in reported general payments places this provider in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 386 | $359,444 |
| JardianceEmpagliflozin | 260 | $287,293 |
| EntrestoSacubitril/Valsartan | 156 | $177,452 |
| XareltoRivaroxaban | 104 | $115,724 |
| Repatha SureclickEvolocumab | 106 | $84,966 |
| BrilintaTicagrelor | 74 | $48,995 |
| FarxigaDapagliflozin Propanediol | 60 | $42,604 |
| Repatha PushtronexEvolocumab | 31 | $27,425 |
| Rosuvastatin Calcium | 1,550 | $15,573 |
| Praluent PenAlirocumab | 23 | $15,539 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $10,333 |
| Atorvastatin Calcium | 978 | $7,827 |
| Metoprolol Succinate | 601 | $7,523 |
| Ezetimibe | 375 | $6,165 |
| Ranolazine ErRanolazine | 54 | $5,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $359,444386 claims |
| Boehringer IngelheimJardiance | $251 | $287,293260 claims |
| Johnson & JohnsonXarelto | $150 | $115,724104 claims |
| AstraZenecaBrilinta, Farxiga, Lokelma | $125 | $101,932146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Houma
- Craig WalkerHouma$5M
- Pradeep NairHouma$212K
- Richard AbbenHouma$101K
- Matthew FinnHouma$69K
- Anil ChagarlamudiHouma$27K
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.